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NKcellsareamajorcomponentoftheinnateimmunesystemandplayanimportantroleinthetissueinﬂammationassociatedwith
autoimmune diseases such as inﬂammatory bowel disease (IBD). NK cells are unique in bearing both stimulatory and inhibitory
receptors speciﬁc for MHC class I molecules, and their function is regulated by a series of inhibiting or activating signals. The
delicate balance between activation and inhibition that decides NK cell ﬁnal action provides an opportunity for their possible
modulatory eﬀect on speciﬁc therapeutic settings. Intestinal NK cells are phenotypically distinct from their counterparts in the
blood and resemble “helper” NK cells, which have potentially important functions both in promoting antipathogen responses
and in the maintenance of intestinal epithelial homeostasis. NK cell activities have been found to be signiﬁcantly below normal
levelsin both remissiveandactive stagesofIBD patients.However,someproinﬂammatorycytokines (e.g.,IL-15,IL-21,andIL-23)
could potently induce NK cell activation to secret high levels of proinﬂammatory cytokines (e.g., IFN-γ and TNF) and promote
the cytolytic activities against the target cells. This paper provides the characteristics of intestinal NK cells and their potential role
in the pathogenesis of IBD.
1.Introduction
Inﬂammatory bowel diseases (IBDs), including Crohn’s dis-
ease (CD) and ulcerative colitis (UC), are chronic inﬂamma-
tory diseases of the gastrointestinal tract. The two conditions
shareanumberofcommoncharacteristics.However,notable
diﬀerences are also observed in these disorders. CD may be
patchy, segmental, and typically transmural inﬂammation
in the gut, which is characterized by the aggregation of
macrophagesthatfrequentlyformnoncaseatinggranulomas.
On the contrary, UC shows the pathological features of a sig-
niﬁcant number of leukocyte inﬁltrations within the lamina
propria and the crypts, where they form microabscesses, as
well as depletion of mucin by goblet cells [1]. Although their
exact etiology is still not completely understood, increasing
data have demonstrated that these conditions occur through
an inappropriateimmune response to asubset of commensal
enteric bacteria in a genetically susceptible host, with disease
initiated by environmental triggers. Dysfunction of the
mucosal immune system evokes intestinal inﬂammation
throughtheactivationofbothinnateandacquiredimmunity
in the gut. Evidence has demonstrated that both T helper 1
(Th1) and Th2 cells are involved in the induction of chronic
gut inﬂammation [2, 3]. CD is a predominately Th1- and
Th17-mediated process, while UC seems to be a Th2-like
disorder. In healthy individuals, such immunopathogenesis
is avoided by the presence of regulatory T cells that inhibit
the inﬂammatory pathway [4]. Among the innate immune
compartments, NK cells are a major component of the
innate immune responses against intracellular pathogens
and participate in the tissue inﬂammation associated with
autoimmune diseases, including IBD [5–7].
2.Immune ResponsesofNK Cells
NK cells are important eﬀector cells of the innate immune
system required for the ﬁrst line of defense against trans-
formed and infected cells and play an essential role in
linking innate and adaptive immunity through their ability
to secrete IFN-γ [5–7]. At the early stage of infection, NK
cells are considered as the primary source of IFN-γ,s h a p i n g2 Journal of Biomedicine and Biotechnology
the adaptive immunity through diﬀerentiation of CD4+ T
cells to the Th1 subsets [8, 9]. NK cells kill their target
cells through two major pathways, both requiring close
contact between NK cells and the target cells. In the ﬁrst
pathway, cytoplasmic granule toxins including perforins and
granzymes are secreted by exocytosis and together induce
apoptosis ofthe target cells. The second pathway involves the
engagement ofdeathreceptors intarget cellsby their cognate
ligands in NK cells, resulting in classical caspase-dependent
apoptosis [8].
Previous studies [7] both in mouse models of autoim-
mune diseases and in humans have shown that NK cells have
either a disease-promoting or -controlling role. Unlike T
cells, NK cells do not express a diverse set of antigen-speciﬁc
receptors, but they are unique in bearing both stimulatory
and inhibitory receptors, and their function is regulated
by a series of inhibiting or activating signals. When NK
cell inhibitory receptors bind to major histocompatibility
complex (MHC) class I molecules, their eﬀector functions
(i.e., cytotoxicityand cytokineproduction) are then blocked.
Lower expression of stimulatory receptors could result from
speciﬁc downregulation of the receptors in such NK cells,
or from a failure of these cells to upregulate such receptors
during development. Moreover, the activation of NK cells
also results from the concerted action of costimulatory
molecules already well characterized for their function in
T cells. However, evidence indicates that NK cells also
regulate the innate and acquired immune responses through
their secretion of soluble factors and/or cell-cell contact
[8]. NK cells discriminate from myeloid immature dendritic
cells, which typically underexpress MHC class I molecules,
and mature dendritic cells, which upregulate MHC class I
expression afterantigen uptake[10].The killing ofimmature
dendriticcellsbyNKcellshasbeeninterpretedasacontrolof
the quality of dendritic cells, allowing only mature dendritic
cells to migrate to the lymph nodes [11].
NK cells develop primarily in the bone marrow in adults
and are widely distributed in the body, but the largest
population can be found in spleen, lung, liver, bone marrow,
and peripheral blood. NK cells can migrate to various tissues
[12]. Intestinal NK cells are phenotypically distinct from
their counterparts in the blood and resemble “helper” NK
cells, which have potentially important functions both in
promoting antipathogen responses and in the maintenance
of intestinal epithelium [13]. It has been suggested that NK
cells in gut, like T cells, require priming for activation, a
process that involves cytokines such as IFN-γ, IL-15, and IL-
18 [13].
3.PathogenicRoleofNK CellsinIBD
3.1. Alteration of Lamina Propria NK Cells in IBD. NK
cells are present within the gut-associated lymphoid tissue
including intraepithelial lymphoid compartment, intestinal
lamina propria, Peyer’s patches, and mesenteric lymphoid
nodes and display a proinﬂammatory cytokine proﬁle (e.g.,
IFN-γ, TNF, IL-2, IL-17, and IL-22) in response to com-
mensal enteric bacteria through the innate immune system
and cytolytic activity, indicating that intestinal NK cells
play an important role in mucosal innate immunity and
tolerance [13–17]. These mucosal NK cells are distinct from
conventional NK cells in the periphery, characterized by the
expression of a transcription factor, RORC in human or
RORγt in mice, CD127 (IL-7Rα) and NKp44 in humans
or NKp46 in mice. CD56 serves as an important marker
deﬁning functionally distinct subsets of NK and NKT
cells based on their ability in the periphery. In humans,
CD56bright NK cells show potential for cytokine secretion,
while CD56dim NK cells have elevated cytotoxicity associated
with a mature diﬀerentiation state. Similar subsets of NK
cells are also found in mice based on their expression of
CD27. Mucosal CD56+ NK cells express a mature phenotype
and produce high amounts of IFN-γ and TNF. A relative
reduction in CD56+ NK cells may conversely have an impact
on intestinal epithelial repair processes in the gastroin-
testinal tract [18, 19]. Recently, NKp46+CD56+CD3− NK
cells have been found in gut lamina propria surrounding
colonic crypts and do not express MHC class I-speciﬁc
killer cell immunoglobulin receptor KIR2D. Phenotypic
analysis reveals that lamina propria NKp46+CD3− NK
cellsareCD127+c-kit+CD122lowCD27lowLy49−.Importantly ,
these subsets of NK cells express RORγt, produce high
level of IL-22 but not IFN-γ and IL-17 after stimulation
in vitro, and lack NK cell cytolytic function [20–22]. These
data indicate that NKp46+CD3− NK cells in gut mucosa
are distinct from conventional NK cells characteristic of
IFN-γ production and cytotoxicity and may be involved in
intestinal epithelial homeostasis and prevention of intestinal
inﬂammation.
The precise role of NK cells in the pathogenesis of IBD is
still elusive. Increasing evidence has indicated that distinct
functional subsets of intestinal mucosal NK cells with an
alteration in activation and cytotoxic activity potentially
contribute to the pathogenesis of IBD [19, 23, 24]. NK cells
have been found to be increased in inﬂamed mucosa of IBD
patients, and NK cell diﬀerentiation is also accelerated in
the lamina propria, suggesting that NK cells are involved in
the disease pathophysiology. CD16+ NK cells are found to
be increased in the lamina propria from both CD and UC
patients compared with healthy controls, and azathioprine
preferentially inhibits proliferation of CD16+ NK cells and
induces apoptosis in resting but not in preactivated NK
cells [23], indicating that NK cells with cytolytic potential
are enriched in the colonic lamina propria of IBD patients
and that azathioprine is associated with a reduction in
these cells and a normalization of NK cell population in
gut mucosa. However, previous work has reported that the
populations of CD161+ NK cells are signiﬁcantly decreased
in the inﬂamed mucosa of UC, whereas the frequency of
conventional CD161+ cells is similar among IBD patient
and healthy controls. These data indicate that colonic lamina
propria CD161+ NK cells are thought to play important
roles as anti-inﬂammatory cells and that the decrease in
the proportions of these cells in inﬂamed colon may be
associated withcolonicinﬂammation progressesinIBD[24].
Although NKp44+ or NKp46+ IL-22-producing NK
cells are present in intestinal mucosa, their role in theJournal of Biomedicine and Biotechnology 3
pathogenesis of IBD is still unknown. Recent work has
demonstrated that peripheral blood CD56+CD3− NK cells
strongly express NKp30, NKp46, CD122, NKG2D, and
CD244, but not NKp44, CD127, and CD69 [25]. On the
contrary, gut lamina propria CD56+CD3− NK cells could
express NKp30, NKp44, NKp46, CD122, CD127, NKG2D,
CD244 and CD69. Interestingly, both NKp44+ and NKp46+
NK cells are found to be present in intestinal mucosa.
NKp44−NKp46+ NKcellspreferentiallyexpresshighlevelsof
CD122butlowlevelsofRORCandCD127andproduceIFN-
γ after stimulation in vitro,w h e r e a sN K p 4 4 +NKp46−NK
cells express high levels of RORC and CD127 and produce
IL-22 [25]. These IFN-γ-producing NKp46+ NK cells are
found to be signiﬁcantly increased in inﬂamed mucosa of
CD patients, while IL-22-producing NKp44+ NK cells are
markedly decreased compared with those in UC patients
and healthy controls. IL-23 could promote NKp46+ NK
cell activation to produce large amounts of IFN-γ.T h e s e
data indicate that the balance between IFN-γ-producing
NKp46+ and IL-22-producing NKp44+ NK cells is disrupted
in inﬂamed mucosa of CD patients and that these NKp46+
NK cells may be involved in the developmentof IBD.
3.2. NK KIR Genotypic Association with IBD. As part of the
innate immune system, NK cells recognize human leukocyte
antigen (HLA) class I molecules in target cells through
their membrane receptors. The main receptors of NK cells
are the killer immunoglobulin-like receptors (KIRs) [26].
The human KIR gene family comprises 15 genes and 2
pseudogenes, which are located within the IBD6 linkage
region at chromosome 19q13.4. KIRs contain either two or
three immunoglobulin-like domains with either long (2DL,
3DL) or short (2DS, 3DS) cytoplasmic tails. The presence
of a long cytoplasmic tail (L) with immune tyrosine-based
motifs (ITIM) permits the transduction of inhibitory signals
and characterizes the inhibitory KIRs (2DL, 3DL), which
inhibit NK- and cytotoxicT cell-mediated lysis of target cells
expressed appropriate HLA class I ligands. In contrast, the
presence of a short cytoplasmic tail (S) is associated with
the activating or noninhibitory KIR (2DS, 3DS), which may
promote cytolysis of target cells [26]. Therefore, a variety
of inhibitory and activating KIRs which recognize and bind
to their HLA class I ligands in target cells could regulate
activation and inhibition of NK cell responses. Various
KIR/HLA combinations may program the diﬀerentiation of
NK cells during immune responses.
Recent genetic association studies have implicated that
both KIR and their ligands display considerable genetic
diversity in the development of several inﬂammatory con-
ditions, including human IBD [26]. KIR and HLA C locus
(HLA-Cw) variants that reduce NK cell inhibition have
been shown to increase susceptibility to the development of
IBD [27]. We have found that the KIR2DL1 and KIR2DL3
gene frequencies are signiﬁcantly lower in UC patients
compared with healthy controls (0.71 versus 0.896; 0.62
versus 0.821). The KIR2DL1 gene phenotype frequency
is markedly decreased in CD patients more than healthy
controls (0.731 versus 0.896). Interestingly, KIR2DL1–HLA-
C2 combination is observed to be decreased in IBD patients
compared with controls (0.38 versus 0.575 in UC; 0.404
versus0.575inCD)[27].These datasuggestthatthedecrease
of combination KIR2DL1 and HLA-C2 may reduce the acti-
vating threshold of NK cells and CTL, enhance the cytolytic
activity of lymphocytes, promote their multiplication, and
ﬁnally lead to immune response to a subset of commensal
enteric bacteria in IBD. Thus, KIR genotype and HLA ligand
interaction may contribute to the genetic susceptibility of
IBD.
3.3. Proinﬂammatory Cytokines in the Induction of NK Cell
Activation in IBD. Previous work has proven that both
stromal cells and cytokine/growth factors play a critical
role in the development of NK cell development. Some
proinﬂammatory cytokines (e.g., IL-2, IL-15, IL-21, and
IL-23) have been observed to be involved in the immune
responses of NK cells under inﬂammatory conditions such
as IBD.
3.3.1. IL-2. IL-2 is a lymphocytotrophic cytokine that is
involved in the growth and diﬀerentiation of T and B
cells and enhances the cytolytic activities of NK cells. It
induces the proliferation of CD4+ and CD8+ T cells by
upregulating and maintaining the expression of the IL-2
receptor (IL-2R) α-subunit, which forms, together with the
β-subunit and γ-subunit, the high-aﬃnity IL-2R. IL-2 is
also required for maturation and development of NK cells
[28]. It has been documented that in vitro expanded NK
cells have increased natural cytotoxicity receptors, TRAIL
and NKG2D expression, and superior tumor cytotoxicity
compared with short-term IL-2-activated NK cells. There is
controversial about the amount of IL-2 in the mucosa of
IBD patients. Some studies have shown that mRNA levels of
IL-2 are increased in inﬂamed mucosa of active CD, while
in other studies, both mRNA and protein levels of IL-2 are
reduced in both CD and UC [29, 30]. IL-2 homeostasis may
lead to preferential depletion of regulatory T-cell subsets,
which cause exacerbation of inﬂammation in the gut [31].
In contrast, it has been conceived that eruption of IBD
is associated with disturbed homeostasis and dominance
of eﬀector cells including colitogenic T-cell clones [32].
Therefore, the disruption of IL-2 signaling may evolve as
a deleterious mechanism in the context of autoimmunity,
rather than an immunosuppressive strategy [31]. Therefore,
IL-2 secreted by intestinal mucosal T cells in IBD may
contribute to NK homeostasis and the development of IBD.
3.3.2.IL-15. IL-15is mainly derivedfrom nonlymphoidcells
andshares many similarities toIL-2.Ithas beenalsofoundto
be produced by intestinal macrophages and other cell types
in response to luminal bacterial stimulation and plays an
important rolein growthand diﬀerentiationofimmune cells
withintheintestinalmucosa,includingTandBlymphocytes,
NK cells, macrophages, and monocytes [33]. IL-15 exerts
most of these eﬀects by binding to a heterotrimeric complex
composed of the IL-2Rβ chain, the IL-2R γcc h a i n ,a n d
the IL-15Rα chain. IL-15 induces T-cell proliferation and
cytokine production, stimulates locomotion and chemotaxis4 Journal of Biomedicine and Biotechnology
of normal T cells, and protects them from apoptosis. Impor-
tantly, IL-15 enhances NK cell cytotoxicity and antibody-
dependent cell-mediated cytotoxicity and upregulates NK
cell survival and production of NK cell-derived cytokines
such as IFN-γ,G M - C S F ,a n dT N F[ 28, 33]. Consistent with
this, IL-15-deﬁcient mice display a marked reduction of
CD8+ T cells, as well as certain intraepithelial lymphocytes.
Incidentally,thesemice also lackNKcells, suggesting thatIL-
15mayalso beinvolvedin expansion andsurvival ofNKcells
[34]. In rodent models of intracellular bacterial infections,
evidence has demonstrated that IL-15 could attract NK
cells to infected sites and limit bacterial colonization [35].
In the intestine IL-15 is observed to stimulate NK, NKT,
and TCRγδ T-cell activation [36]. However, after IL-15
treatment, both intraepithelial lymphocytes and NK cells
have a greater killing potential against target cells [37].
Given that IL-15 is markedly increased in inﬂamed mucosa
of IBD [38], IL-15 is also thought to be involved in the
induction of NK cell activation and immune responses in
IBD.
3.3.3. IL-21. IL-21 is a member of the IL-2 family of
cytokines, expressed mainly by CD4+ T cells, including
Th1, Th2, and Th17 cells, and recently implicated in Th17
cell diﬀerentiation. IL-21R is structurally related to IL-
2 Ra n dI L - 1 5 Ra n de x p r e s s e di nT ,N K ,B ,a n dd e n d r i t i c
cells. IL-21 has been found to stimulate T-cell proliferation
and diﬀerentiation, enhance clonal expansion of antigen-
activated na¨ ıve CD4+ and CD8+ T cells, and induce the gene
encoding IFN-γ, IL-18R, IL-2Rα, IL-12Rβ2, and the Th1-
associated transcription factor T-bet in activated memory T
cells [39, 40]. IL-21 also synergized with IL-15 and IL-18 in
stimulating IFN-γ gene expression in these same cultures.
Wurster et al. [41] reported that exposing na¨ ıve CD4+ T cells
to IL-21 under conditions that skew diﬀerentiation towards
t h eT h 1p h e n o t y p ea c t ually inhibited IFN-γ production
although it had little eﬀect on other Th1 cytokines such
as TNF or IL-2. IL-21 is also associated with the Th2-
mediated immune response and plays a role in inhibiting
the diﬀerentiation of naive Th cells into IFN-γ-producing
Th1 cells. Moreover, IL-21 is found to promote human NK
cell maturation and activation in synergy with IL-15, Ftl-3
ligand, and stem cell factor and enhance IFN-γ production
and cytotoxicity [42].
IL-21 is involved in both cell-mediated and humoral
responses and plays an important role in the pathogenesis
of several autoimmune diseases, including IBD [39, 40].
Increased expression of IL-21 and IL-21R has been observed
in the inﬂamed mucosa of IBD patients [43, 44]. We
found that IL21R-positive cells are mainly expressed in
CD4+,C D 8 + T, B, and NK cells from peripheral blood
and lamina propria of IBD patients [44]. IL-21 could
expand already polarized IL-17A-producingcellsin inﬂamed
mucosa, promote a local inﬂammatory response in gut
mucosa, and trigger intestinal mucosal T-cell activation and
proinﬂammatory cytokine secretion [44]. Importantly, IL-
21 could promote IBD NK cell activation to produce high
levels of proinﬂammatory cytokines (e.g., IFN-γ and TNF)
and enhance cytotoxicity against target cells. Our ﬁndings
have conﬁrmed that IL-21 is involved in the pathogenesis
of IBD via the induction of NK cell activation and its
cytolytic activity against target cells (e.g., intestinal epithelial
cells). These data indicate that target immune therapy
directed against IL-21R signaling may be warranted in some
experimental colitis models, and that blockade of the IL-21R
signaling pathway may have a therapeutic potential in IBD
[45].
3.3.4. IL-23. IL-23 and IL-12 are members of a small
family of proinﬂammatory heterodimer cytokines, sharing
a common p40 subunit covalently linked either to a p35
subunit to form IL-12 or to a p19 subunit to form IL-23
[46]. IL-23R is predominantly expressed in T, NK, NKT
cells, and, to a smaller extent, in monocytes, macrophages,
and dendritic cells. After binding to the IL-23R, IL-23
preferentially induces memory T-cell activation. Evidence
has demonstrated that IL-23 exhibits some similar biological
activities to IL-12. However, in comparison with IL-12 with
profound induction ofTh1 immune response, aswell as pro-
motion of cytolytic,antimicrobial, and antitumor responses,
IL-23 is found to play a critical role in the maintenance of
immune response by controlling T-cell memory function
and by inﬂuencing the proliferation and survival of IL-17-
producing Th17 cells [47].
IL-23 has been reported to be increased expression in the
sera and inﬂamed colon of IBD patients [48, 49]. Genome-
wide association studies indicate that IL-23R is involved
in the diﬀerentiation of Th17 cells, and is associated with
susceptibility to CD and partly also to UC [50]. Our recent
work has shown that the frequencies of IL-23R expression in
CD4+,C D 8 + T cells and NK cells are signiﬁcantly increased
in peripheral blood and lamina propria mononuclear cells
from IBD patients compared with healthy controls [49].
Importantly, we found that IL-23 strongly induces IBD
NK cell activation, showing increased secretion of proin-
ﬂammatory cytokines (e.g., IFN-γ and TNF) and cytolytic
activities. These ﬁndings indicate that IL-23 produced by
intestinal mucosal macrophages/dendritic cells in inﬂamed
mucosa of IBD could promote peripheral blood NK cell
eﬀectorresponse.Recentworkhasdemonstratedtwodistinct
subsets of intestinal mucosal NKp46+ NK cells according
to the expression of RORγt. The RORγt− subset functions
as typical NK cells dependently on IL-15 but not on
RORγt and displays NK cell activities (e.g., cytotoxicity
and IFN-γ secretion), whereas the RORγt+ subpopulation
develops independently of IL-15 but required RORγt[ 21,
22]. Most interestingly, these CD3−NKp46+ cells located
in the intestinal mucosa express RORγta n dI L - 2 2b u t
not IL-17A in response to IL-23 stimulation, and these
cells lack normal NK cell function such as expression of
perforin and IFN-γ, indicating that these NK cells play
an important role in mucosal homeostasis and protectable
immune response, particularly under microbial challenge
[20]. These data suggest that intestinal mucosal NK cells
mayalsobeassociatedwithproinﬂammatory responseunder
inﬂammatory conditions and play an important role in
mucosal homeostasis and defense against luminal microbial
challenge although the precise role ofIL-23 in the inductionsJournal of Biomedicine and Biotechnology 5
intestinal mucosal NK cell eﬀect response need to be further
investigated.
4.Conclusions
NK cells play an important role in linking innate and
adaptive immunity. Evidence has proven that NK cells have
a disease-promoting or -controlling role in autoimmune
diseases, depending on the disease and the NK cell subset
analyzed. Thus, ongoing studies should focus on intestinal
mucosal NK cells and their interactions with other immune
cells in inﬂamed mucosa of IBD, and these will provide
powerful insights into potential role of NK cells in the
pathogenesis of IBD.
Abbreviations
CD: Crohn’s disease
HLA: Human leukocyte antigen
IBD: Inﬂammatory bowel disease
KIR: Killer immunoglobulin-like receptor
NK: Natural killer cells
UC: Ulcerative colitis.
Acknowledgment
This work was supported by the Grants from the National
Natural Science Foundation of China (nos. 30971358 and
81061120521).
References
[1] R. J. Xavier and D. K. Podolsky, “Unravelling the pathogenesis
ofinﬂammatoryboweldisease,”Nature, vol.448,no.7152,pp.
427–434, 2007.
[2] R. B. Sartor, “Mechanisms of disease: pathogenesis of Crohn’s
disease and ulcerative colitis,” Nature Clinical Practice Gas-
troenterology and Hepatology, vol. 3, no. 7, pp. 390–407, 2006.
[3] Z.J .Liu,P .K.Y adav ,J .L.Su,J .S.W ang,andKE.F ei,“P ot ential
role of Th17 cells in the pathogenesis of inﬂammatory bowel
disease,” World Journal of Gastroenterology, vol. 15, no. 46, pp.
5784–5788, 2009.
[4] T. T. Macdonald and G. Monteleone, “Immunity, inﬂamma-
tion, and allergy in the gut,” Science, vol. 307, no. 5717, pp.
1920–1925, 2005.
[5] E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini,
“Functions of natural killer cells,” Nature Immunology,v o l .9 ,
no. 5, pp. 503–510, 2008.
[6] A. H. Jonssonand W. M. Yokoyama, “Chapter 2 natural killer
cell tolerance. Licensing and other mechanisms,” Advances in
Immunology, vol. 101, pp. 27–79, 2009.
[7] N. Schleinitz, E. V´ ely, J. R. Harl´ e, and E. Vivier, “Natural killer
cells in human autoimmune diseases,” Immunology, vol. 131,
no. 4, pp. 451–458, 2010.
[8] A. Mart´ ın-Fontecha, L. L. Thomsen, S. Brett et al., “Induced
recruitment of NK cells to lymph nodes provides IFN-γ for
T(H)1 priming,” Nature Immunology,vol. 5, no. 12, pp. 1260–
1265, 2004.
[9] M.J.Smyth,E.Cretney ,J.M.K ellyetal.,“ A ctivationofNKcell
cytotoxicity,” Molecular Immunology, vol. 42, no. 4, pp. 501–
510, 2005.
[ 1 0 ]Y .Z h a n g ,D .L .W a l l a c e ,C .M .d eL a r ae ta l . ,“ In vivo kinetics
of human natural killer cells: the eﬀects of ageing and acute
and chronic viral infection,” Immunology, vol. 121, no. 2, pp.
258–265, 2007.
[ 1 1 ]A .M o r e t t a ,E .M a r c e n a r o ,S .S i v o r i ,M .D .C h i e s a ,M .V i t a l e ,
and L. Moretta, “Early liaisons between cells of the innate
immune system in inﬂamed peripheral tissues,” Trends in
Immunology, vol. 26, no. 12, pp. 668–675, 2005.
[ 1 2 ]T .W a l z e r ,M .B l´ ery, J. Chaix et al., “Identiﬁcation, activation,
and selective in vivo ablation of mouse NK cells via NKp46,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 104, no. 9, pp. 3384–3389, 2007.
[13] S. L. Sanos and A. Diefenbach, “Isolation of NK cells and
NK-like cells from the intestinal lamina propria,” Methods in
Molecular Biology, vol. 612, pp. 505–517, 2010.
[14] F. Le` o n ,E .R o l d ´ an, L. Sanchez, C. Camarero, A. Bootello,
and G. Roy, “Human small-iintestinal epithelium contains
functional natural killer lymphocytes,” Gastroenterology,v o l .
125, no. 2, pp. 345–356, 2003.
[15] E. Vivier, H. Spits, and T. Cupedo, “Interleukin-22-producing
innate immune cells: new players in mucosal immunity and
tissue repair?” Nature Reviews Immunology,v o l .9 ,n o .4 ,p p .
229–234, 2009.
[16] H. Veiga-Fernandes,D. Kioussis,and M.Coles, “Natural killer
receptors: the burden of a name,” Journal of Experimental
Medicine, vol. 207, no. 2, pp. 269–272, 2010.
[17] T. Cupedo, N. K. Crellin, N. Papazian et al., “Human fetal
lymphoid tissue-inducer cells are interleukin 17-producing
precursors to RORC CD127 natural killer-like cells,” Nature
Immunology, vol. 10, no. 1, pp. 66–74, 2009.
[18] O. Cohavy and S. R. Targan, “CD56 marks an eﬀector T cell
subset in the human intestine,” Journal of Immunology,v o l .
178, no. 9, pp. 5524–5532, 2007.
[ 1 9 ]S .C .N g ,S .P l a m o n d o n ,H .O .A l - H a s s ie ta l . ,“ An o v e lp o p -
ulation of human CD56 human leucocyte antigen D-related
(HLA-DR+) colonic lamina propria cells is associated with
inﬂammation in ulcerative colitis,” Clinical and Experimental
Immunology, vol. 158, no. 2, pp. 205–218, 2009.
[20] M. Cella, A. Fuchs, W. Vermi et al., “A human natural killer
cell subset provides an innate source of IL-22 for mucosal
immunity,” Nature, vol. 457, no. 7230, pp. 722–725, 2009.
[21] C. Luci, A. Reynders, I. I. Ivanov et al., “Inﬂuence of the
transcription factor RORγt on the development of NKp46
+
cell populations in gut and skin,” Nature Immunology,v o l .1 0 ,
no. 1, pp. 75–82, 2009.
[22] S.L.Sanos,V.L.Bui,A.Morthaetal.,“RORγta n dc o m m e n s a l
microﬂora are required for the diﬀerentiation of mucosal
interleukin 22-producing NKp46
+ cells,” Nature Immunology,
vol. 10, no. 1, pp. 83–91, 2009.
[23] A. W. Steel, C. M. Mela, J. O. Lindsay, B. G. Gazzard, and
M. R. Goodier, “Increased proportion of CD16(+) NK cells
in the colonic lamina propria of inﬂammatory bowel disease
patients, but not after azathioprine treatment,” Alimentary
Pharmacology and Therapeutics, vol. 33, no. 1, pp. 115–126,
2011.
[24] M. Shimamoto, Y. Ueno, S. Tanaka et al., “Selective decrease
in colonic CD56(+) T and CD161(+) T cells in the inﬂamed
mucosa of patients with ulcerative colitis,” World Journal of
Gastroenterology, vol. 13, no. 45, pp. 5995–6002, 2007.
[25] T. Takayama, N. Kamadax, H. Chinen et al., “Imbalance of
NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer
cells in the intestinal mucosaofpatients with Crohn’s disease,”
Gastroenterology, vol. 139, no. 3, pp. 882–892, 2010.6 Journal of Biomedicine and Biotechnology
[26] S. I. Khakoo and M. Carrington, “KIR and disease: a model
systemorsystemofmodels?”ImmunologicalReviews,vol.214,
no. 1, pp. 186–201, 2006.
[27] H. Zhang, S. Liu, Z. Liu, and J. Li, “Expression of iKIR-HLA-
Cw in patients with inﬂammatory bowel disease,” Life Science
Journal, vol. 5, no. 4, pp. 17–22, 2008.
[28] B. Becknell and M. A. Caligiuri, “Interleukin-2, interleukin-
15, and their roles in human natural killer cells,” Advances in
Immunology, vol. 86, pp. 209–239, 2005.
[ 2 9 ]P .D e s r e u m a u x ,E .B r a n d t ,L .G a m b i e ze ta l . ,“ D i s t i n c t
cytokine patterns in early and chronic ileal lesions of Crohn’s
disease,” Gastroenterology, vol. 113, no. 1, pp. 118–126, 1997.
[30] W. Hsu, W. Zhang, K. Tsuneyama et al., “Diﬀerential mecha-
nisms in the pathogenesis of autoimmune cholangitis versus
inﬂammatory bowel disease in interleukin-2Rα−/− mice,”
Hepatology, vol. 49, no. 1, pp. 133–140, 2009.
[31] K. Kameyamax, Y. Nemoto, T. Kanai et al., “IL-2 is positively
involved in the development of colitogenic CD4+ IL-7Rα
high memory T cells in chronic colitis,” European Journal of
Immunology, vol. 40, no. 9, pp. 2423–2436, 2010.
[32] E. C. Ebert, A. Panja, K. M. Das et al., “Patients with inﬂam-
matory bowel disease may have a transforminggrowth factor-
β-, interleukin (IL)-2- or IL-10-deﬁcient state induced by
intrinsic neutralizing antibodies,” Clinical and Experimental
Immunology, vol. 155, no. 1, pp. 65–71, 2009.
[33] V. Budagian, E. Bulanova, R. Paus, and S. Bulfone-Paus,
“IL-15/IL-15 receptor biology: a guided tour through an
expanding universe,” Cytokineand Growth Factor Reviews,v o l .
17, no. 4, pp. 259–280, 2006.
[ 3 4 ] A .W .G o l d r a t h ,P .V .S i v a k u m a r ,M .G l a c c u me ta l . ,“ C y t o k i n e
requirements for acute and basal homeostatic proliferation
of na¨ ıve and memory CD8+ T cells,” Journal of Experimental
Medicine, vol. 195, no. 12, pp. 1515–1522, 2002.
[ 3 5 ]D .J u l l i e n ,P .A .S i e l i n g ,K .U y e m u r a ,N .D .M a r ,T .H .R e a ,
and R. L. Modlin, “IL-15, an immunomodulator of T cell
responses in intracellular infection,” Journal of Immunology,
vol. 158, no. 2, pp. 800–806, 1997.
[36] N. Ohta, T. Hiroi, M. N. Kweon et al., “IL-15-
dependent activation-induced cell death-resistant Th1
type CD8αβ+NK1.1+ T cells for the development of small
intestinal inﬂammation,” Journal of Immunology, vol. 169, no.
1, pp. 460–468, 2002.
[37] E. C. Ebert, “IL-15 converts human intestinal intraepithelial
lymphocytes to CD94 produces of IFN-γ and IL-10, the latter
promoting Fas ligand-mediated cytotoxicity,” Immunology,
vol. 115, no. 1, pp. 118–126, 2005.
[38] Z. Liu, K. Geboes, S. Colpaert, G. R. D’Haens, P. Rutgeerts,
andJ.L.Ceuppens,“IL-15ishighlyexpressed ininﬂammatory
bowel disease and regulates local T cell-dependent cytokine
production,” Journal of Immunology, vol.164, no. 7, pp. 3608–
3615, 2000.
[39] R. Spolski and W. J. Leonard, “IL-21 is an immune activator
that also mediates suppression via IL-10,” Critical Review of
Immunology, vol. 30, no. 6, pp. 559–570, 2010.
[40] R. Spolski and W. J. Leonard, “Interleukin-21: basic biology
and implications for cancer and autoimmunity,” Annual
Review of Immunology, vol. 26, pp. 57–79, 2008.
[41] A. L. Wurster, V. L. Rodgers, A. R. Satoskar et al., “Interleukin
21 is a T helper (Th) cell 2 cytokine that speciﬁcally inhibits
the diﬀerentiation of naive Th cells into interferon gamma-
producing Th1 cells,” Journal of Experimental Medicine,v o l .
196, no. 7, pp. 969–977, 2002.
[42] J. Parrish-Novak, S. R. Dillon, A. Nelson et al., “Interleukin
21 and its receptor are involved in NK cell expansion and
regulation oflymphocytefunction,”Nature, vol.408,no.6808,
pp. 57–63, 2000.
[43] G. Monteleone, I. Monteleone, D. Fina et al., “Interleukin-
21 enhances T-helper cell type I signaling and interferon-γ
production in Crohn’s disease,” Gastroenterology, vol. 128, no.
3, pp. 687–694, 2005.
[44] Z.Liu,L.Yang,Y. Cui etal.,“IL-21enhancesNK cell activation
and cytolytic activity and induces Th17 cell diﬀerentiation
in inﬂammatorybowel disease,” Inﬂammatory Bowel Diseases,
vol. 15, no. 8, pp. 1133–1144, 2009.
[45] G. Monteleone, F. Pallone, and T. T. Macdonald,“Interleukin-
21 asanew therapeutic target forimmune-mediated diseases,”
Trends in Pharmacological Sciences,vol.30, no. 8,pp. 441–447,
2009.
[46] B. Oppmann, R. Lesley, B. Blom et al., “Novel p19 protein
engages IL-12p40 to form a cytokine, IL-23, with biological
activities similaras well asdistinct fromIL-12,”Immunity,v o l .
13, no. 5, pp. 715–725, 2000.
[ 4 7 ]T .K o r n ,E .B e t t e l l i ,M .O u k k a ,a n dV .K .K u c h r o o ,“ I L - 1 7a n d
Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–
517, 2009.
[48] C. Schmidt, T. Giese, B. Ludwig et al., “Expression of
interleukin-12-related cytokine transcripts in inﬂammatory
bowel disease: elevated interleukin-23p19 and interleukin-
27p28 in Crohn’s disease but not in ulcerative colitis,”
Inﬂammatory Bowel Diseases, vol. 11, no. 1, pp. 16–23, 2005.
[49] Z. Liu, P. K. Yadav, X. Xu et al., “The increased expression of
IL-23 in inﬂammatory bowel disease promotes intraepithelial
and lamina propria lymphocyte inﬂammatory responses and
cytotoxicity,” Journal of Leukocyte Biology,v o l .8 9 ,n o .4 ,p p .
597–606, 2011.
[ 5 0 ]R .H .D u e r r ,K .D .T a y l o r ,S .R .B r a n te ta l . ,“ Ag e n o m e - w i d e
association study identiﬁes IL23R as an inﬂammatory bowel
disease gene,” Science,vol.314,no.5804,pp. 1461–1463,2006.